A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis
Public ClinicalTrials.gov record NCT02969525. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to evaluate the dose response based on the efficacy, safety and tolerability of bimekizumab in subjects with active psoriatic arthritis.
Study identification
- NCT ID
- NCT02969525
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2016 (Actual)
- Primary completion
- Nov 2017 (Actual)
- Completion
- Jul 2018 (Actual)
- Last update posted
- Mar 20, 2023
2016 – 2018
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pa0008 007 | San Diego | California | 92037 | — |
| Pa0008 005 | Aventura | Florida | 33180 | — |
| Pa0008 003 | Hagerstown | Maryland | 21740 | — |
| Pa0008 011 | Lansing | Minnesota | 48910 | — |
| Pa0008 025 | Lexington | New York | 40504 | — |
| Pa0008 014 | Portland | Oregon | 97239 | — |
| Pa0008 001 | Duncansville | Pennsylvania | 16635 | — |
| Pa0008 012 | Johnston | Rhode Island | 02919 | — |
| Pa0008 004 | Charleston | South Carolina | 29406-93 | — |
| Pa0008 010 | Jackson | Tennessee | 38305 | — |
| Pa0008 006 | Dallas | Texas | 75231 | — |
| Pa0008 013 | Mesquite | Texas | 75150 | — |
| Pa0008 002 | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02969525, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2023 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02969525 live on ClinicalTrials.gov.